Subsequently in vivo studies have shown that knocking out CAMKK2 in a transgenic model of prostate cancer driven by phosphatase and tensin homologue (PTEN) loss impairs tumorigenesis [6]. The gene discussed is CAMKK2; the disease is prostate carcinoma.